2,919,110 Shares in Kailera Therapeutics, Inc. $KLRA Acquired by Wellington Management Group LLP

Key Points

• Wellington Management acquired 2.92 million Kailera Therapeutics shares during the second quarter, valued at approximately $64.3 million and representing a 2.25% stake.
• Kailera’s stock opened at $15.85, near its 12-month low of $15.15, while the company reported a quarterly loss of $1.09 per share—worse than analysts’ expected loss of $0.74.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and an average price target of $42.75, despite ratings ranging from “Strong Buy” to “Sell.”

Wellington Management Group LLP bought a new position in shares of Kailera Therapeutics, Inc. (NASDAQ:KLRA - Free Report) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm bought 2,919,110 shares of the company's stock, valued at approximately $64,308,000. Wellington Management Group LLP owned 2.25% of Kailera Therapeutics as of its most recent filing with the SEC.

Kailera Therapeutics Stock Down 3.4%

NASDAQ KLRA opened at $15.85 on Thursday. The firm has a 50 day simple moving average of $18.73. The firm has a market capitalization of $2.05 billion and a P/E ratio of -0.00. Kailera Therapeutics, Inc. has a 12-month low of $15.15 and a 12-month high of $28.23.

Kailera Therapeutics (NASDAQ:KLRA - Get Free Report) last announced its earnings results on Wednesday, August 12th. The company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.35). On average, sell-side analysts predict that Kailera Therapeutics, Inc. will post -3.89 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on KLRA. TD Cowen initiated coverage on shares of Kailera Therapeutics in a research report on Tuesday, May 12th. They set a "buy" rating and a $57.00 price objective for the company. Weiss Ratings began coverage on shares of Kailera Therapeutics in a research note on Friday, August 14th. They issued a "sell (d)" rating for the company. William Blair initiated coverage on Kailera Therapeutics in a report on Tuesday, May 12th. They set an "outperform" rating for the company. Jefferies Financial Group assumed coverage on Kailera Therapeutics in a research note on Tuesday, May 12th. They issued a "buy" rating and a $48.00 price target on the stock. Finally, Leerink Partners assumed coverage on Kailera Therapeutics in a report on Tuesday, May 12th. They issued an "outperform" rating and a $36.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Kailera Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $42.75.

Kailera Therapeutics Profile

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.

Want to see what other hedge funds are holding KLRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kailera Therapeutics, Inc. (NASDAQ:KLRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source